Oncomatryx
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2p Parque Tecnológico De Bizkaia 801b, D...Phone Number
+34 946087037Website
www.oncomatryx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Oncomatryx
A clinical-stage biotech company pioneering Tumor Quantum Immunotherapy. The company's team has been devoted to the development of precision drugs targeting the tumor microenvironment for over a decade. The company aims to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors.Explore more
Oncomatryx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncomatryx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Oncomatryx is spiking on competitors!
Earning: See what the market has to say on Oncomatryx recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Oncomatryx had a recent Job posting/layoffs
Oncomatryx, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oncomatryx has new funding data
Check if Oncomatryx has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Oncomatryx launches new products
Congratulate Masked Content for being promoted to Masked Content at Oncomatryx
Recommended Actions
Reach out to Masked Content who joined Oncomatryx as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Oncomatryx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncomatryx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncomatryx.
Oncomatryx financials insights
Gather financial insights about Oncomatryx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$16.2M
2025
Other Financing Round
$26M
Other Financing Round
$12M
Oncomatryx Tech Stack
A closer look at the technologies used by Oncomatryx
Most Recent Scoops
Funding
Funding
Partnership
Partnership, Research & Development, Medical Research, Pharmaceuticals
Funding
Funding
Mergers & Acquisitions (M&A)
Funding
Oncomatryx News & Media
TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
LUND, Sweden, May 6, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting the tumor microenvironment. TFS...TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
LUND, Sweden, May 6, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting the tumor microenvironment. TFS...ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials
ZAMUDIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación. This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to tOncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment
ZAMUDIO, Spain--(BUSINESS WIRE)--Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncomatryx
Sign Up For FreeTo access detailed company insights
A clinical-stage biotech company pioneering Tumor Quantum Immunotherapy. The company's team has been devoted to the development of precision drugs targeting the tumor microenvironment for over a decade. The company aims to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors.... Read More
